Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (360)	11/21/1999 5:29:00 PM
From: Casaubon	Read Replies (2) \| Respond to of 1169

it should be possible to design, based on the structure of FK506, non-FKBP-12-binding (nonimmunosuppressant) compounds That's the easy part. We did that for years! Does Timcodar promote neurite outgrowth? Or, does small molecule ligand which bind to FKBP-12 actually also bind to PKBP-52 (new ligand for FK506) and enhance wonted effects? Are you asking if Timcodar promotes neurite outgrowth directly, or requires a FKBP mediated binding event? I doubt Timcodar functions directly on neurite outgrowth as the presence of NGF is necessary to promote nerve growth. Whether or not it is an FKBP mediated event is debateable.